Inogen, Inc. Logo

Inogen, Inc.

INGN

(1.2)
Stock Price

10,05 USD

-34.81% ROA

-45.37% ROE

-2.35x PER

Market Cap.

217.977.610,00 USD

11.43% DER

0% Yield

-28.3% NPM

Inogen, Inc. Stock Analysis

Inogen, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Inogen, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.48x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (8%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-31.98%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-28.2%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-83) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Inogen, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Inogen, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Inogen, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Inogen, Inc. Revenue
Year Revenue Growth
2011 30.634.000
2012 48.576.000 36.94%
2013 75.443.000 35.61%
2014 112.537.000 32.96%
2015 159.005.000 29.22%
2016 202.829.000 21.61%
2017 249.438.000 18.69%
2018 358.111.000 30.35%
2019 361.943.000 1.06%
2020 308.487.000 -17.33%
2021 358.003.000 13.83%
2022 377.241.000 5.1%
2023 335.868.000 -12.32%
2023 315.660.000 -6.4%
2024 355.060.000 11.1%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Inogen, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 1.789.000
2012 2.262.000 20.91%
2013 2.398.000 5.67%
2014 2.977.000 19.45%
2015 4.180.000 28.78%
2016 5.113.000 18.25%
2017 5.313.000 3.76%
2018 7.029.000 24.41%
2019 9.401.000 25.23%
2020 14.080.000 33.23%
2021 16.576.000 15.06%
2022 21.943.000 24.46%
2023 17.956.000 -22.2%
2023 20.840.000 13.84%
2024 17.712.000 -17.66%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Inogen, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 5.623.000
2012 8.289.000 32.16%
2013 13.754.000 39.73%
2014 17.942.000 23.34%
2015 25.658.000 30.07%
2016 31.793.000 19.3%
2017 37.576.000 15.39%
2018 38.018.000 1.16%
2019 37.121.000 -2.42%
2020 38.605.000 3.84%
2021 37.852.000 -1.99%
2022 43.905.000 13.79%
2023 68.044.000 35.48%
2023 75.260.000 9.59%
2024 74.272.000 -1.33%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Inogen, Inc. EBITDA
Year EBITDA Growth
2011 1.589.000
2012 5.911.000 73.12%
2013 4.464.000 -32.41%
2014 10.465.000 57.34%
2015 28.761.000 63.61%
2016 22.731.000 -26.53%
2017 29.656.000 23.35%
2018 37.892.000 21.74%
2019 19.789.000 -91.48%
2020 -12.025.000 264.57%
2021 9.240.000 230.14%
2022 42.593.000 78.31%
2023 94.724.000 55.03%
2023 -46.232.000 304.89%
2024 -2.760.000 -1575.07%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Inogen, Inc. Gross Profit
Year Gross Profit Growth
2011 14.704.000
2012 23.949.000 38.6%
2013 38.991.000 38.58%
2014 55.517.000 29.77%
2015 76.258.000 27.2%
2016 97.310.000 21.63%
2017 121.237.000 19.74%
2018 178.580.000 32.11%
2019 171.861.000 -3.91%
2020 138.180.000 -24.37%
2021 176.483.000 21.7%
2022 153.533.000 -14.95%
2023 135.056.000 -13.68%
2023 136.542.000 1.09%
2024 188.600.000 27.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Inogen, Inc. Net Profit
Year Net Profit Growth
2011 -2.002.000
2012 564.000 454.96%
2013 25.435.000 97.78%
2014 6.826.000 -272.62%
2015 11.585.000 41.08%
2016 20.519.000 43.54%
2017 21.002.000 2.3%
2018 51.845.000 59.49%
2019 20.950.000 -147.47%
2020 -5.829.000 459.41%
2021 -6.333.000 7.96%
2022 -83.772.000 92.44%
2023 -182.876.000 54.19%
2023 -102.449.000 -78.5%
2024 -22.360.000 -358.18%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Inogen, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 0 0%
2013 1 100%
2014 0 0%
2015 1 0%
2016 1 100%
2017 1 0%
2018 2 50%
2019 1 0%
2020 0 0%
2021 0 0%
2022 -4 100%
2023 -8 57.14%
2023 -4 -75%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Inogen, Inc. Free Cashflow
Year Free Cashflow Growth
2011 -7.101.000
2012 -8.444.000 15.9%
2013 -4.675.000 -80.62%
2014 -540.000 -765.74%
2015 25.672.000 102.1%
2016 23.018.000 -11.53%
2017 50.267.000 54.21%
2018 47.004.000 -6.94%
2019 34.079.000 -37.93%
2020 19.416.000 -75.52%
2021 -434.000 4573.73%
2022 -58.754.000 99.26%
2023 -30.245.000 -94.26%
2023 -3.104.000 -874.39%
2024 1.718.000 280.68%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Inogen, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 1.859.000
2012 4.004.000 53.57%
2013 13.467.000 70.27%
2014 15.697.000 14.21%
2015 38.161.000 58.87%
2016 31.034.000 -22.97%
2017 60.494.000 48.7%
2018 59.977.000 -0.86%
2019 40.593.000 -47.75%
2020 37.013.000 -9.67%
2021 23.633.000 -56.62%
2022 -37.532.000 162.97%
2023 -3.234.000 -1060.54%
2023 2.185.000 248.01%
2024 6.689.000 67.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Inogen, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 8.960.000
2012 12.448.000 28.02%
2013 18.142.000 31.39%
2014 16.237.000 -11.73%
2015 12.489.000 -30.01%
2016 8.016.000 -55.8%
2017 10.227.000 21.62%
2018 12.973.000 21.17%
2019 6.514.000 -99.16%
2020 17.597.000 62.98%
2021 24.067.000 26.88%
2022 21.222.000 -13.41%
2023 27.011.000 21.43%
2023 5.289.000 -410.7%
2024 4.971.000 -6.4%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Inogen, Inc. Equity
Year Equity Growth
2011 7.556.000
2012 28.575.000 73.56%
2013 56.299.000 49.24%
2014 118.150.000 52.35%
2015 134.018.000 11.84%
2016 182.088.000 26.4%
2017 227.041.000 19.8%
2018 310.424.000 26.86%
2019 344.621.000 9.92%
2020 349.623.000 1.43%
2021 370.227.000 5.57%
2022 297.406.000 -24.49%
2023 204.812.000 -45.21%
2023 230.630.000 11.19%
2024 187.595.000 -22.94%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Inogen, Inc. Assets
Year Assets Growth
2011 24.131.000
2012 47.586.000 49.29%
2013 82.397.000 42.25%
2014 140.085.000 41.18%
2015 161.314.000 13.16%
2016 214.049.000 24.64%
2017 275.072.000 22.18%
2018 375.898.000 26.82%
2019 447.339.000 15.97%
2020 461.852.000 3.14%
2021 489.513.000 5.65%
2022 405.041.000 -20.86%
2023 326.194.000 -24.17%
2023 343.696.000 5.09%
2024 308.919.000 -11.26%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Inogen, Inc. Liabilities
Year Liabilities Growth
2011 16.575.000
2012 19.011.000 12.81%
2013 26.098.000 27.16%
2014 21.935.000 -18.98%
2015 27.296.000 19.64%
2016 31.961.000 14.6%
2017 48.031.000 33.46%
2018 65.474.000 26.64%
2019 102.718.000 36.26%
2020 112.229.000 8.47%
2021 119.286.000 5.92%
2022 107.635.000 -10.82%
2023 121.382.000 11.33%
2023 113.066.000 -7.35%
2024 121.324.000 6.81%

Inogen, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
13.83
Net Income per Share
-3.91
Price to Earning Ratio
-2.35x
Price To Sales Ratio
0.67x
POCF Ratio
222.13
PFCF Ratio
-11.06
Price to Book Ratio
1.16
EV to Sales
0.42
EV Over EBITDA
-31.73
EV to Operating CashFlow
141.18
EV to FreeCashFlow
-7
Earnings Yield
-0.43
FreeCashFlow Yield
-0.09
Market Cap
0,22 Bil.
Enterprise Value
0,14 Bil.
Graham Number
26.45
Graham NetNet
1.68

Income Statement Metrics

Net Income per Share
-3.91
Income Quality
-0.01
ROE
-0.45
Return On Assets
-0.3
Return On Capital Employed
-0.38
Net Income per EBT
1
EBT Per Ebit
1.02
Ebit per Revenue
-0.28
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0.24
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.44
Operating Profit Margin
-0.28
Pretax Profit Margin
-0.28
Net Profit Margin
-0.28

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.04
Free CashFlow per Share
-0.83
Capex to Operating CashFlow
21.18
Capex to Revenue
0.06
Capex to Depreciation
1.02
Return on Invested Capital
-0.43
Return on Tangible Assets
-0.35
Days Sales Outstanding
41.44
Days Payables Outstanding
43.64
Days of Inventory on Hand
47.67
Receivables Turnover
8.81
Payables Turnover
8.36
Inventory Turnover
7.66
Capex per Share
0.88

Balance Sheet

Cash per Share
5,13
Book Value per Share
7,94
Tangible Book Value per Share
6.11
Shareholders Equity per Share
7.94
Interest Debt per Share
0.98
Debt to Equity
0.11
Debt to Assets
0.07
Net Debt to EBITDA
18.41
Current Ratio
2.7
Tangible Asset Value
0,14 Bil.
Net Current Asset Value
0,07 Bil.
Invested Capital
232928000
Working Capital
0,12 Bil.
Intangibles to Total Assets
0.14
Average Receivables
0,04 Bil.
Average Payables
0,02 Bil.
Average Inventory
24324500
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Inogen, Inc. Dividends
Year Dividends Growth

Inogen, Inc. Profile

About Inogen, Inc.

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

CEO
Mr. Kevin R. M. Smith
Employee
834
Address
301 Coromar Drive
Goleta, 93117

Inogen, Inc. Executives & BODs

Inogen, Inc. Executives & BODs
# Name Age
1 Dr. Krishna Jhaveri
Chief Medical Officer
70
2 Mr. Adrien Mithalal
Senior Vice President of Research & Development
70
3 Mr. Paul Andreassi
Senior Vice President of Quality & Regulatory Affairs
70
4 Ms. Jennifer Yi Boyer
Executive Vice President & Chief Human Resources Officer
70
5 Mr. Grgoire Ramade
Executive Vice President & Chief Commercial Officer
70
6 Mr. Kevin R. M. Smith
President, Chief Executive Officer & Director
70
7 Mr. Michael J. Bourque
Executive Vice President, Chief Financial Officer & Treasurer
70
8 Mr. Philip Corrin
Senior Vice President of Operations & Supply Chain
70
9 Mr. Kevin P. Smith
General Counsel & Executive Vice President of Business Development
70

Inogen, Inc. Competitors

NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)
Surmodics, Inc. Logo
Surmodics, Inc.

SRDX

(0.8)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
CVRx, Inc. Logo
CVRx, Inc.

CVRX

(1.0)
Artivion, Inc. Logo
Artivion, Inc.

AORT

(0.5)
Heska Corporation Logo
Heska Corporation

HSKA

(1.0)
CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
NuVasive, Inc. Logo
NuVasive, Inc.

NUVA

(1.0)
SI-BONE, Inc. Logo
SI-BONE, Inc.

SIBN

(1.0)